

December 11, 1964

Dr. Edward V. Henry
Assistant Director
Clinical Investigation
McNeil Laboratories, Inc.
Fort Washington, Pa.

Dear Dr. Henry:

We have received supplies of Trifluoperidol and are now able to continue our program. Mr. Genter called me yesterday morning. As we were in the midst of a time limited administrative transfer, I was unable to spend the time with him and the new representative, as you requested in your letter.

Following your visit, we have reduced the dosage of medication in all the patients and they are now in a dosage range of 4-10 mg. per day. We have also withdrawn the anti-parkinson medication, and at these dosage levels, the clinical manifestations of parkinsonism are great. Within the next two weeks, we will reinstitute the antiparkinson medication and our data should be more comparable to those of other laboratories. At the time of your visit, you indicated that there may be other institutions or other records regarding the high dosage of Trifluoperidol, such as we thought were necessary. I would be grateful for any references that you may have regarding this high dosage so that we may be able to write a better documented report.

Thank you for your cooperation.

Sincerely yours,

Max Fink, M.D.
Director

mf;ls